Clinical trials indicated that the KRAS gene mutations are associated with both resistance for reversible EGFR TKIs (epidermal growth factor receptor tyrosine kinase inhibitors: gefitinib, erlotinib) and in reduction of overall survival (OS) in NSCLC patients. This evidence concerns the gene EGFR and non-small cell lung carcinoma.